{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-107248","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.650881+00:00","generated_at":"2026-06-10T03:58:33.456368+00:00","sec_items":["1.01","5.03","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health amends royalty agreements, issues warrants and preferred to reduce debt by $1.5M","bullets":["Amended three $12M royalty interests (Iliad, Uptown, Streeterville); monthly payment Jan 2026 = greater of $750k or actual.","Issued warrants to purchase 750,000 shares total at $0.37/share to investors; 5-year term exercisable cash or cashless.","Exchanged $1.5M of Uptown's royalty balance for 118 shares of Series I Convertible Preferred Stock, convertible at $0.264/share.","Series I preferred has 9.99% beneficial ownership cap, no voting rights, and ranks pari passu with common on liquidation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-107248","json":"https://secwatch.observer/filing/0001104659-23-107248.json","markdown":"https://secwatch.observer/filing/0001104659-23-107248.md","text":"https://secwatch.observer/filing/0001104659-23-107248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923107248/0001104659-23-107248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923107248/tm2327745d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:58:33.456368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b58492363393a849d125b727e7fa5ff36d120d5d","claim":"Jaguar Health, Inc.: Filed Certificate of Designation for Series I Convertible Preferred Stock, effective September 29, 2023 (effective 2023-09-29).","evidence_excerpt":"the Company agreed to issue shares of Series I Preferred Stock to Uptown. The preferences, rights, limitations and other matters relating to the Series I Preferred Stock are set forth in the Certificate of Designation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923107248/0001104659-23-107248-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"governance_change"},{"claim_id":"0bf7076b681723fd5c0ecf1d0210e3efbe19f49a","claim":"Jaguar Health, Inc. amended Royalty Interest Global Amendments with Iliad Research and Trading, L.P., Uptown Capital, LLC, Streeterville Capital, LLC valued at $12 million (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on January 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the ac","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923107248/0001104659-23-107248-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Iliad Research and Trading, L.P., Uptown Capital, LLC, Streeterville Capital, LLC"},{"label":"Value","value":"$12 million"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"},{"claim_id":"f03f6d04903b20012a737376be42066732f8b864","claim":"Jaguar Health, Inc. entered into Exchange Agreement with Uptown Capital, LLC valued at $1,500,000.00 (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, the Company entered into a privately negotiated exchange agreement with Uptown (the “Exchange Agreement”), pursuant to which the Company issued an aggregate of 118 shares of the Company’s newly authorized Series I Convertible Preferred Stock (the “Series I Preferred Stock”) to Uptown, at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Exchange Agreement, in exchange for a $1,500,000.00 reduction in the outstanding balance of the December 2020 Royalty Interest (the “Exchange Transaction”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923107248/0001104659-23-107248-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Uptown Capital, LLC"},{"label":"Value","value":"$1,500,000.00"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}